Clinical Trials

16 enrolled 13 charts

Carcinoma, Hepatocellular, Stomach Neoplasms

NCT04209686 2025-12-03

Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

36 enrolled

Stomach Neoplasms

NCT03797326 2025-11-17

LEAP-005

BreastCNSGastrointestinalGynecologic

611 enrolled 27 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03505320 2025-10-20

ILUSTRO

143 enrolled

Neoplasms, Stomach Neoplasms

NCT04768686 2025-09-25

FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer

20 enrolled 14 charts

Stomach Neoplasms

NCT05104567 2025-09-24

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

138 enrolled 32 charts

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Carcinoma, Hepatocellular, Stomach Neoplasms, Colorectal Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

613 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT04069273 2025-07-31

SEQUEL

Phase 2 Recruiting

58 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT05379972 2025-07-16

Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

9 enrolled

Stomach Neoplasms

NCT05311176 2025-05-11

nextHERIZON

7 enrolled 8 charts

Stomach Neoplasms

NCT03064490 2025-04-10

PROCEED

35 enrolled 8 charts

Stomach Neoplasms

NCT04508140 2024-11-29

Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis

18 enrolled 13 charts

Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT04745988 2024-11-15

An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer

43 enrolled

Stomach Neoplasms

NCT03382600 2024-06-11

KEYNOTE-659

100 enrolled 21 charts

Stomach Neoplasms

NCT03321630 2024-03-27

A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies

24 enrolled 10 charts

Stomach Neoplasms

NCT06036745 2024-03-07

Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen

Phase 2 Recruiting

20 enrolled

Stomach Neoplasms

NCT02918162 2024-02-15

Perioperative Chemo and Pembrolizumab in Gastric Cancer

49 enrolled 10 charts

Adenocarcinoma, Stomach Neoplasms

NCT03196232 2024-01-23

Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer

3 enrolled 12 charts

GastrointestinalGynecologic

Esophageal Neoplasms, Stomach Neoplasms

NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Phase 2 Recruiting

24 enrolled

Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Stomach Neoplasms, Urogenital Neoplasms

NCT03488667 2023-05-19

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

40 enrolled

Adenocarcinoma, Stomach Neoplasms

NCT02954536 2023-03-16

Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

37 enrolled 8 charts

Esophageal Neoplasms, Stomach Neoplasms

NCT04099641 2023-02-08

An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients

80 enrolled 14 charts

Stomach Neoplasms

NCT04510285 2023-02-01

A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection

1 enrolled 8 charts

Esophageal Neoplasms, Stomach Neoplasms

NCT02335411 2022-08-08

KEYNOTE-059

318 enrolled 24 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04632459 2022-03-11

Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer

Phase 2 Unknown

35 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Stomach Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03122548 2019-04-04

Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers

5 enrolled 11 charts

Adenocarcinoma Of Esophagus, Digestive System Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Stomach Diseases, Stomach Neoplasms

NCT02943603 2018-07-13

A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach

Phase 2 Withdrawn